Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?
- 1 December 2008
- journal article
- review article
- Published by Elsevier BV in Trends in Pharmacological Sciences
- Vol. 30 (1), 1-7
- https://doi.org/10.1016/j.tips.2008.10.001
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteinsProceedings of the National Academy of Sciences of the United States of America, 2008
- Activation of hypothalamic S6 kinase mediates diet-induced hepatic insulin resistance in ratsJCI Insight, 2008
- Leptin controls adipose tissue lipogenesis via central, STAT3–independent mechanismsNature Medicine, 2008
- Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic painBritish Journal of Pharmacology, 2008
- Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptorsNature Neuroscience, 2007
- Multiple pathways involved in the biosynthesis of anandamideNeuropharmacology, 2007
- Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysisBritish Journal of Pharmacology, 2007
- Abdominal obesity and metabolic syndromeNature, 2006
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006
- Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesityJCI Insight, 2000